# Biotech Pharmaceutical Co., Ltd.: Phase 1 study in Asthma (20 participants)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Biotech Pharmaceutical Co., Ltd. |
| Sponsor type | Academic and hospital |
| Study | A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma |
| NCT ID | NCT07886710 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Asthma |
| Intervention types | biological |
| Target enrollment | 20 |
| Posted | 2026-10-21 |
| Planned start | 2026-09-30 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07886710). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.